Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Juvenile Macular Degeneration Pipeline Drugs Market Overview

Juvenile Macular Degeneration is mostly found in the form of Stargardt disease. Stargardt’s disease can occur with symptoms that include blurry or fuzzy vision, dark, empty spots in the center of vision, and difficulty reading or performing detail work.

The Juvenile Macular Degeneration pipeline drugs market research report provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects.

Key Targets in the Juvenile Macular Degeneration Pipeline Drugs Market

The key targets of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter, Acetylcholinesterase, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Complement C5, Complement Factor D, Peroxisome Proliferator Activated Receptor Alpha, Peroxisome Proliferator Activated Receptor Delta, Peroxisome Proliferator Activated Receptor Gamma, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Retinoid Isomerohydrolase, Retinol Binding Protein 4, and Transthyretin.

Juvenile Macular Degeneration Pipeline Drugs Market, by Targets

Juvenile Macular Degeneration Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Juvenile Macular Degeneration Pipeline Drugs Market

The mechanisms of action of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter Activator, Acetylcholinesterase Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Complement C5 Inhibitor, Complement Factor D Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Peroxisome Proliferator Activated Receptor Delta Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/KInhibitor, Retinoid Isomerohydrolase Inhibitor, Retinol Binding Protein 4 Inhibitor, and Transthyretin Inhibitor.

Juvenile Macular Degeneration Pipeline Drugs Market, by Mechanisms of Action

Juvenile Macular Degeneration Pipeline Drugs Market, by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Juvenile Macular Degeneration Pipeline Drugs Market

The routes of administration in the Juvenile Macular Degeneration pipeline drugs market are oral, intravitreal, intraocular, ophthalmic, and subcutaneous.

Juvenile Macular Degeneration Pipeline Drugs Market, by Routes of Administration

Juvenile Macular Degeneration Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Juvenile Macular Degeneration Pipeline Drugs Market

The molecule types in the Juvenile Macular Degeneration pipeline drugs market are gene therapy, small molecule, cell therapy, aptamer, antisense oligonucleotide, antisense RNAi oligonucleotide, and recombinant enzyme.

Juvenile Macular Degeneration Pipeline Drugs Market, by Molecule Types

Juvenile Macular Degeneration Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Juvenile Macular Degeneration Pipeline Drugs Market Companies

Some of the key companies in the Juvenile Macular Degeneration pipeline drugs market are Astellas Pharma Inc, IVERIC bio Inc, 4P-Pharma SAS, Alkeus Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Alpine Biotherapeutics Corp, Applied Genetic Technologies Corp, Beam Therapeutics Inc, Belite Bio Inc, and Biophytis SA.

Juvenile Macular Degeneration Pipeline Drugs Market, by Key Companies

Juvenile Macular Degeneration Pipeline Drugs Market, by Key Companies

To know more about key companies, download a free report sample

Market Report Overview

Key Targets Retinal Specific ATP Binding Cassette Transporter, Acetylcholinesterase, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Complement C5, Complement Factor D, Peroxisome Proliferator Activated Receptor Alpha, Peroxisome Proliferator Activated Receptor Delta, Peroxisome Proliferator Activated Receptor Gamma, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Retinoid Isomerohydrolase, Retinol Binding Protein 4, and Transthyretin
Key Mechanisms of Action Retinal Specific ATP Binding Cassette Transporter Activator, Acetylcholinesterase Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Complement C5 Inhibitor, Complement Factor D Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Peroxisome Proliferator Activated Receptor Delta Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/KInhibitor, Retinoid Isomerohydrolase Inhibitor, Retinol Binding Protein 4 Inhibitor, and Transthyretin Inhibitor
Key Routes of Administration Oral, Intravitreal, Intraocular, Ophthalmic, and Subcutaneous
Key Molecule Types Gene Therapy, Small Molecule, Cell Therapy, Aptamer, Antisense Oligonucleotide, Antisense RNAi Oligonucleotide, and Recombinant Enzyme
Key Companies Astellas Pharma Inc, IVERIC bio Inc, 4P-Pharma SAS, Alkeus Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Alpine Biotherapeutics Corp, Applied Genetic Technologies Corp, Beam Therapeutics Inc, Belite Bio Inc, and Biophytis SA

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Ophthalmology).
  • Reviews of pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Juvenile Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Juvenile Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Ophthalmology)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline

4P-Pharma SAS
Alkeus Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alpine Biotherapeutics Corp
Applied Genetic Technologies Corp
Astellas Pharma Inc
Beam Therapeutics Inc
Belite Bio Inc
Biophytis SA
Brooklyn ImmunoTherapeutics Inc
Cardax Inc
Coave Therapeutics
Copernicus Therapeutics Inc
Curative Biotechnology Inc
Fera Pharmaceuticals LLC
Generation Bio Co
Grupo Ferrer Internacional SA
IVERIC bio Inc
jCyte Inc
Katairo GmbH
Kubota Vision Inc
Lysoclear Inc
Mediphage Bioceuticals Inc
Nanoscope Therapeutics Inc
Oak bay Biosciences Ltd
ProQR Therapeutics NV
Ray Therapeutics Inc
ReVision Therapeutics Inc
Saliogen Therapeutics Inc
Shape Therapeutics Inc
Spark Therapeutics Inc
Splice Bio SL
Stargazer Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Juvenile Macular Degeneration (Stargardt Disease) – Overview

Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Juvenile Macular Degeneration (Stargardt Disease) – Companies Involved in Therapeutics Development

4P-Pharma SAS

Alkeus Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Alpine Biotherapeutics Corp

Applied Genetic Technologies Corp

Astellas Pharma Inc

Beam Therapeutics Inc

Belite Bio Inc

Biophytis SA

Brooklyn ImmunoTherapeutics Inc

Cardax Inc

Coave Therapeutics

Copernicus Therapeutics Inc

Curative Biotechnology Inc

Fera Pharmaceuticals LLC

Generation Bio Co

Grupo Ferrer Internacional SA

IVERIC bio Inc

jCyte Inc

Katairo GmbH

Kubota Vision Inc

Lysoclear Inc

Mediphage Bioceuticals Inc

Nanoscope Therapeutics Inc

Oak bay Biosciences Ltd

ProQR Therapeutics NV

Ray Therapeutics Inc

ReVision Therapeutics Inc

Saliogen Therapeutics Inc

Shape Therapeutics Inc

Spark Therapeutics Inc

Splice Bio SL

Stargazer Pharmaceuticals Inc

Juvenile Macular Degeneration (Stargardt Disease) – Drug Profiles

4P-020 – Drug Profile

Product Description

Mechanism Of Action

ALK-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Aptamer to Inhibit CFD for Juvenile Macular Degeneration (Stargardt Disease) – Drug Profile

Product Description

Mechanism Of Action

ASP-7317 – Drug Profile

Product Description

Mechanism Of Action

History of Events

avacincaptad pegol sodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

BIO-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CDX-301 – Drug Profile

Product Description

Mechanism Of Action

CTxABCA-4 – Drug Profile

Product Description

Mechanism Of Action

ecothiopate iodide – Drug Profile

Product Description

Mechanism Of Action

History of Events

emixustat hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

FAB-111 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy 1 to Activate ABCA4 for Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene therapy for Juvenile Macular Degeneration (Stargardt Disease) – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy To Activate ABCA4 for Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate ABCA4 for Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

GTSG – Drug Profile

Product Description

Mechanism Of Action

Jcell – Drug Profile

Product Description

Mechanism Of Action

History of Events

Lead program in Stargardt disease – Drug Profile

Product Description

Mechanism Of Action

metformin – Drug Profile

Product Description

Mechanism Of Action

History of Events

miniABCA4: STGD1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

QR-1011 – Drug Profile

Product Description

Mechanism Of Action

RAY-001 – Drug Profile

Product Description

Mechanism Of Action

Recombinant Enzyme for Age Related Macular Degeneration and Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

REV-0100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SHP-261 – Drug Profile

Product Description

Mechanism Of Action

soraprazan – Drug Profile

Product Description

Mechanism Of Action

History of Events

Stargardt – Drug Profile

Product Description

Mechanism Of Action

Stargardt Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Stem Cell Therapy for Ophthalmology – Drug Profile

Product Description

Mechanism Of Action

History of Events

STG-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TFB for Dry Age-Related Macular Degeneration, Stargardt Macular Dystrophy – Drug Profile

Product Description

Mechanism Of Action

tinlarebant – Drug Profile

Product Description

Mechanism Of Action

History of Events

VMCO-1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

vutrisiran – Drug Profile

Product Description

Mechanism Of Action

History of Events

Juvenile Macular Degeneration (Stargardt Disease) – Dormant Projects

Juvenile Macular Degeneration (Stargardt Disease) – Product Development Milestones

Featured News & Press Releases

Apr 12, 2022: Fera Pharmaceuticals announces FDA Orphan Designation of Phospholine Iodide for the treatment of Stargardt disease

Jan 25, 2022: Nanoscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt macular degeneration patients

Jan 10, 2022: Nanoscope awarded key U.S. patent protecting its multi-characteristic Opsin Gene Therapy platform for reversing blindness

Aug 25, 2021: Aequus strengthens clinical experience in Stargardt disease with pediatric ophthalmology expertise

Jul 14, 2021: FDA grants Alkeus Pharmaceuticals Breakthrough Therapy designation for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt Disease

Jun 30, 2021: Belite Bio announces start of LBS-008 phase 3 Stargardt Disease trial

Mar 03, 2021: Nanoscope president to deliver talk on gene therapy for retinal diseases at Association for Ocular Pharmacology and Therapeutics conference

Jan 25, 2021: Nanoscope Therapeutics receives Orphan Drug Designation for gene therapy of blindness

Nov 24, 2020: Kubota Vision announces publication of Emixustat’s pharmacodynamic effects in patients with stargardt disease

Oct 28, 2020: reVision Therapeutics announces US FDA Grant of rare pediatric disease and orphan-drug designation for REV-0100 for the treatment of Stargardt disease

Aug 20, 2020: Kubota Vision receives orphan products clinical trials grants to Emixustat for stargardt disease

Jul 20, 2020: Belite Bio announces positive results from phase 1 clinical trials of LBS-008

May 01, 2020: Kubota Vision completes enrollment in the Emixustat phase 3 clinical trial in patients with Stargardt disease

Feb 13, 2020: Acucela provides update on Emixustat phase 3 clinical trial in patients with Stargardt disease

Jan 06, 2020: Acucela announces publication assessing the role of Emixustat Hydrochloride in retinal degeneration treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by 4P-Pharma SAS, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Alkeus Pharmaceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Alnylam Pharmaceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Alpine Biotherapeutics Corp, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Applied Genetic Technologies Corp, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Astellas Pharma Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Beam Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Belite Bio Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Biophytis SA, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Brooklyn ImmunoTherapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Cardax Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Coave Therapeutics, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Copernicus Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Curative Biotechnology Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Fera Pharmaceuticals LLC, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Generation Bio Co, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Grupo Ferrer Internacional SA, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by IVERIC bio Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by jCyte Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Katairo GmbH, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Kubota Vision Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Lysoclear Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Mediphage Bioceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Nanoscope Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Oak bay Biosciences Ltd, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by ProQR Therapeutics NV, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Ray Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by ReVision Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Saliogen Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Shape Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Spark Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Splice Bio SL, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Stargazer Pharmaceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

  • What are the targets of the Juvenile Macular Degeneration pipeline drugs market?

    The targets of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter, Acetylcholinesterase, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Complement C5, Complement Factor D, Peroxisome Proliferator Activated Receptor Alpha, Peroxisome Proliferator Activated Receptor Delta, Peroxisome Proliferator Activated Receptor Gamma, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Retinoid Isomerohydrolase, Retinol Binding Protein 4, and Transthyretin.

  • What are the mechanisms of action of the Juvenile Macular Degeneration pipeline drugs market?

    Some of the mechanisms of action of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter Activator, Acetylcholinesterase Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Complement C5 Inhibitor, Complement Factor D Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Peroxisome Proliferator Activated Receptor Delta Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/KInhibitor, Retinoid Isomerohydrolase Inhibitor, Retinol Binding Protein 4 Inhibitor, and Transthyretin Inhibitor.

  • What are the routes of administration in the Juvenile Macular Degeneration pipeline drugs market?

    The routes of administration in the Juvenile Macular Degeneration pipeline drugs market are oral, intravitreal, intraocular, ophthalmic, and subcutaneous.

  • What are the molecule types in the Juvenile Macular Degeneration pipeline drugs market?

    The molecule types in the Juvenile Macular Degeneration pipeline drugs market are gene therapy, small molecule, cell therapy, aptamer, antisense oligonucleotide, antisense RNAi oligonucleotide, and recombinant enzyme.

  • Which are the key companies in the Juvenile Macular Degeneration pipeline drugs market?

    Some of the key companies in the Juvenile Macular Degeneration pipeline drugs market are Astellas Pharma Inc, IVERIC bio Inc, 4P-Pharma SAS, Alkeus Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Alpine Biotherapeutics Corp, Applied Genetic Technologies Corp, Beam Therapeutics Inc, Belite Bio Inc, and Biophytis SA.

Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.